Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
REGULATORY
Drug Pricing Rules to Be Applied to Oncolytic Virus Delytact: Chuikyo
Japan’s all-important reimbursement policy panel on June 23 agreed to apply drug pricing rules for Daiichi Sankyo’s Delytact (G47∆; teserpaturev), the world’s first-ever oncolytic virus approved for the treatment of malignant glioma. Delytact was granted conditional, time-limited approval on June…
To read the full story
Related Article
- J-TEC’s Ocural, Cell Sheet for Eye Disease, Launched in Japan
December 13, 2021
- Daiichi Sankyo Launches Oncolytic Virus Delytact in Japan
November 2, 2021
- J-TEC’s Oral Mucosal Cell Sheet Ocural Earns NHI Listing
September 16, 2021
- Delytact Gets 1.43 Million Yen Price Tag
August 4, 2021
- Architect of Oncolytic Virus Therapy Looks to Its Use in All Solid Cancers in 5 Years
June 25, 2021
- Japan Approves J-TEC’s Mucosal Cell Sheet for Corneal Stem Cell Deficiency
June 14, 2021
- Japan Approves 1st Oncolytic Virus, Delytact, for Malignant Glioma
June 14, 2021
- MHLW Panel Backs Japan’s 1st Oncolytic Virus for Conditional Approval
May 25, 2021
- Daiichi Sankyo Files Sakigake-Designated Oncolytic Virus in Japan After Overcoming Manufacturing Issues
January 6, 2021
- J-TEC Files Mucosal Cell Sheet for Corneal Epithelial Stem Cell Deficiency in Japan
September 15, 2020
- Submission of Oncolytic Virus G47Δ Lagging as Team Still Preps for Manufacturing
July 22, 2019
REGULATORY
- MHLW’s FY2025 Budget Includes 7.7 Billion Yen to Drive Drug Commercialization
January 6, 2025
- Japan Approves Zepbound, Qalsody, and Lots More Drugs
December 27, 2024
- Quality Assurance and Lag/Loss Fight to Form Pillars of PMD Act Amendment
December 27, 2024
- LDP Members Urge Ministers to End “Mechanical” Off-Year Price Cuts
December 27, 2024
- Japan to Set Up Fund to Spur Generic Shakeup; CEA, Market Expansion Re-Pricing on Agenda
December 26, 2024
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…